AGP Executive Report
Last update: 7 hours agoTreatment Advances: Rusfertide improved hematocrit control and reduced phlebotomy in polycythemia vera, with reported gains in fatigue and symptom burden. In a phase 2 C. difficile trial, LMN-201 plus antibiotics achieved an 83.3% global cure rate versus 36.4% with placebo; recurrence was 9.1% versus 55.6%. Precision Medicine: Prime editing repaired a GATA2 mutation in patient-derived stem cells in preclinical research. An Indian AI-based breast cancer test aims to help identify early-stage patients who may not benefit from chemotherapy. AI in Care: Cancer specialists say AI can help identify people eligible for lung screening, but human counseling and representative training data remain essential. Public Health: Nigeria confirmed an Ebola case, with health authorities tracing 44 contacts as an outbreak spreads in the region. Industry & Access: Median net launch prices for new drugs rose 35% from 2022 to 2025, reaching $257,000, keeping affordability in focus. Medtech executives also expect more small acquisitions and portfolio cuts.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[Finding the Few: Combining Clinical Insight, Data and Media to Reach Patients with Rare Diseases]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/29634124-951295997-2adc13feb93bc72e52d3dad1677b05d211109622-660x372-200x113.png)
